The list of one-hit makers is ranked by how high their first single climbed on the charts compared with how low their sophomore efforts peaked on the charts.
With biotech rallying, investors who really want some bang for their buck should consider three smaller (but more risky) stocks, each one featuring strong charts and low price tags.